Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2024-10-10 00:00:00 ET · period of report 2024-10-08 · accession 0001415889-24-024992 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2024-10-10 | 2024-10-08+ | ELVN | Lyssikatos Joseph P | CSO | S - Sale | $28.11 | -51.1K | 1.05M | -5% | -$1.44M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-09 | S | D | 3,589 | $28.52 | 1,016,035 | I See footnote | — | — | (F5) This transaction was executed in multiple trades at prices ranging from $28.50 to $28.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. |
| 2 | Common | Common Stock | 2024-10-09 | S | D | 34,289 | $28.12 | 1,019,624 | I See footnote | — | — | (F4) This transaction was executed in multiple trades at prices ranging from $27.50 to $28.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. |
| 3 | Common | Common Stock | 2024-10-08 | S | D | 100 | $28.51 | 1,053,913 | I See footnote | — | — | (F3) The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. |
| 4 | Common | Common Stock | 2024-10-08 | S | D | 13,167 | $27.96 | 1,054,013 | I See footnote | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $27.50 to $28.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. |